Comparison of Machine-Learning Models for the Prediction of 1-Year Adverse Outcomes of Patients Undergoing Primary Percutaneous Coronary Intervention for Acute St-Elevation Myocardial Infarction Publisher Pubmed



Tofighi S¹ ; Poorhosseini H¹ ; Jenab Y¹ ; Alidoosti M¹ ; Sadeghian M¹ ; Mehrani M¹ ; Tabrizi Z² ; Hashemi P³ Show Affiliations
Source: Clinical Cardiology Published:2024

Abstract

Background: Acute ST-elevation myocardial infarction (STEMI) is a leading cause of mortality and morbidity worldwide, and primary percutaneous coronary intervention (PCI) is the preferred treatment option. Hypothesis: Machine learning (ML) models have the potential to predict adverse clinical outcomes in STEMI patients treated with primary PCI. However, the comparative performance of different ML models for this purpose is unclear. Methods: This study used a retrospective registry-based design to recruit consecutive hospitalized patients diagnosed with acute STEMI and treated with primary PCI from 2011 to 2019, at Tehran Heart Center, Tehran, Iran. Four ML models, namely Gradient Boosting Machine (GBM), Distributed Random Forest (DRF), Logistic Regression (LR), and Deep Learning (DL), were used to predict major adverse cardiovascular events (MACE) during 1-year follow-up. Results: A total of 4514 patients (3498 men and 1016 women) were enrolled, with MACE occurring in 610 (13.5%) subjects during follow-up. The mean age of the population was 62.1 years, and the MACE group was significantly older than the non-MACE group (66.2 vs. 61.5 years, p <.001). The learning process utilized 70% (n = 3160) of the total population, and the remaining 30% (n = 1354) served as the testing data set. DRF and GBM models demonstrated the best performance in predicting MACE, with an area under the curve of 0.92 and 0.91, respectively. Conclusion: ML-based models, such as DRF and GBM, can effectively identify high-risk STEMI patients for adverse events during follow-up. These models can be useful for personalized treatment strategies, ultimately improving clinical outcomes and reducing the burden of disease. © 2023 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.